Pathophysiology of refractory overactive bladder
Li-Chen Chen
Department of Urology, Mackay Memorial Hospital, Taipei, Taiwan
Department of Medicine, Mackay Medical College, Taipei, Taiwan
Search for more papers by this authorCorresponding Author
Hann-Chorng Kuo
Department of Urology, Buddhist Tzu Chi General Hospital and Tzu Chi University, Hualien, Taiwan
Correspondence
Hann-Chorng Kuo, Department of Urology, Buddhist Tzu Chi General Hospital and Tzu Chi University, No. 707, Sec. 3, Zhongyang Rd., Hualien City, Hualien County 970, Taiwan.
Email: [email protected]
Search for more papers by this authorLi-Chen Chen
Department of Urology, Mackay Memorial Hospital, Taipei, Taiwan
Department of Medicine, Mackay Medical College, Taipei, Taiwan
Search for more papers by this authorCorresponding Author
Hann-Chorng Kuo
Department of Urology, Buddhist Tzu Chi General Hospital and Tzu Chi University, Hualien, Taiwan
Correspondence
Hann-Chorng Kuo, Department of Urology, Buddhist Tzu Chi General Hospital and Tzu Chi University, No. 707, Sec. 3, Zhongyang Rd., Hualien City, Hualien County 970, Taiwan.
Email: [email protected]
Search for more papers by this authorAbstract
Overactive bladder (OAB) is a common condition. The International Continence Society defines OAB as a symptom complex characterized by urgency with or without urge incontinence, usually with frequency and nocturia. The first-line treatment for OAB includes behavioral therapy, such as caffeine reduction, fluid intake modification, weight reduction, bladder training, and pelvic floor muscle training, as well as treatment with antimuscarinic or β3-adrenoceptor agonist medications. However, less than half of all cases achieve satisfactory outcomes following first-line treatment. Second-line therapy considered if satisfactory responses are not achieved after 8 to 12 weeks treatment with first-line therapy include intradetrusor botulinum toxin injection, neuromodulation, and surgical treatment. Patients with refractory OAB may have more severe symptoms or underlying pathophysiologies that were not resolved by the initial medication. The pathophysiologies of refractory OAB include occult neurogenic bladder, undetected bladder outlet obstruction, urethral-related OAB, urothelial dysfunction with aging, chronic bladder ischemia, chronic bladder inflammation, central sensitization, and autonomic dysfunction. This article discusses the possible pathophysiologies of refractory OAB.
REFERENCES
- 1Stewart WF, Van Rooyen JB, Cundiff GW, et al. Prevalence and burden of overactive bladder in the United States. World J Urol. 2003; 20: 327-336.
- 2Chuang YC, Liu SP, Lee KS, et al. Prevalence of overactive bladder in China, Taiwan and South Korea: results from a cross-sectional, population-based study. Low Urin Tract Symptoms. 2019; 11: 48-55.
- 3Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn. 2002; 21: 167-178.
- 4Yamaguchi O, Honda K, Nomiya M, et al. Defining overactive bladder as hypersensitivity. Neurourol Urodyn. 2007; 26(Suppl): 904-907.
- 5Nabi G, Cody JD, Ellis G, Herbison P, Hay-Smith J. Anticholinergic drugs versus placebo for overactive bladder syndrome in adults. Cochrane Database Syst Rev. 2006; 4: CD003781.
- 6Wyman JF, Burgio KL, Newman DK. Practical aspects of lifestyle modifications and behavioural interventions in the treatment of overactive bladder and urgency urinary incontinence. Int J Clin Pract. 2009; 63: 1177-1191.
- 7Smith A, Bevan D, Douglas HR, James D. Management of urinary incontinence in women: summary of updated NICE guidance. BMJ. 2013; 347: f5170.
- 8Wong J, Tincello DG. Management of refractory overactive bladder. TOG. 2016; 18: 173-181. https://doi.org/10.1111/tog.12265.
- 9Phe V, deWachter S, Roupret M, Chartier-Kastler E. How to define a refractory idiopathic overactive bladder?Neurourol Urodyn. 2015; 34: 2-11.
- 10Abrams P, Andersson KE, Birder L, et al. Fourth International Consultation on Incontinence Recommendations of the International Scientific Committee: evaluation and treatment of urinary incontinence, pelvic organ prolapse, and fecal incontinence. Neurourol Urodyn. 2010; 29: 213-240.
- 11Tudor KI, Sakakibara R, Panicker JN. Neurogenic lower urinary tract dysfunction: evaluation and management. J Neurol. 2016; 263: 2555-2564.
- 12Bayliss M, Wu C, Newgreen D, Mundy AR, Fry CH. A quantitative study of atropine-resistant contractile responses in human detrusor smooth muscle, from stable, unstable and obstructed bladders. J Urol. 1999; 162: 1833-1839.
- 13O'Reilly BA, Kosaka AH, Knight GF, et al. P2X receptors and their role in female idiopathic detrusor instability. J Urol. 2002; 167: 157-164.
- 14Pannek J, Janek S, Sommerer F, Tannapfel A. Expression of purinergic P2X2-receptors in neurogenic bladder dysfunction due to spinal cord injury: a preliminary immunohistochemical study. Spinal Cord. 2009; 47: 561-564.
- 15Blok BF, Holstege G. The central nervous system control of micturition in cats and humans. Behav Brain Res. 1998; 92: 119-125.
- 16Andrew J, Nathan PW. Lesions on the anterior frontal lobes and disturbances of micturition and defaecation. Brain. 1964; 87: 233-262.
- 17Fowler CJ, Griffiths D, deGroat WC. The neural control of micturition. Nat Rev Neurosci. 2008; 9: 453-466.
- 18Oelke M, Bachmann A, Descazeaud A, et al. EAU guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction. Eur Urol. 2013; 64: 118-140.
- 19McVary KT, Roehrborn CG, Avins AL, et al. Update on AUA guideline on the management of benign prostatic hyperplasia. J Urol. 2011; 185: 1793-1803.
- 20Athanasopoulos AA, Perimenis PS. Comparison of doxazosin with or without tolterodine in men with symptomatic bladder outlet obstruction and an overactive bladder. BJU Int. 2005; 95: 1117-1118.
- 21Jiang YH, Wang CC, Kuo HC. Videourodynamic findings of lower urinary tract dysfunctions in men with persistent storage lower urinary tract symptoms after medical treatment. PLoS One. 2018; 13: e0190704.
- 22Fan YH, Lin AT, Chen KK. Defining causes for overactive bladder symptoms in women. Low Urin Tract Symptoms. 2012; 4: 73-76.
- 23Hsiao S-M, Lin H-H, Kuo H-C. Videourodynamic studies of women with voiding dysfunction. Sci Rep. 2017; 7: 6845.
- 24McCloskey KD. Interstitial cells in the urinary bladder: localization and function. Neurourol Urodyn. 2010; 29: 82-87.
- 25Czaja K, Sienkiewicz W, Vittoria A, Costagliola A, Cecio A. Neuroendocrine cells in the female urogenital tract of the pig, and their immunohistochemical characterization. Acta Anat (Basel). 1996; 157: 11-19.
- 26Grol S, vanKoeveringe GA, deVente J, vanKerrebroeck PE, Gillespie JI. Regional differences in sensory innervation and suburothelial interstitial cells in the bladder neck and urethra. BJU Int. 2008; 102: 870-877.
- 27Robain G, Combrisson H, Mazieres L. Bladder response to urethral flow in the awake ewe. Neurourol Urodyn. 2001; 20: 641-649.
- 28Shafik A, Shafik AA, El-Sibai O, Ahmed I. Role of positive urethrovesical feedback in vesical evacuation. The concept of a second micturition reflex: the urethrovesical reflex. World J Urol. 2003; 21: 167-170.
- 29Shafik A, el-Sibai O, Ahmed I. Effect of urethral dilation on vesical motor activity: identification of the urethrovesical reflex and its role in voiding. J Urol. 2003; 169: 1017-1019.
- 30Birder LA, deWachter S, Gillespie J, Wyndaele JJ. Urethral sensation: basic mechanisms and clinical expressions. Int J Urol. 2014; 21(Suppl 1): 13-16.
- 31Griffiths D, Tadic SD, Schaefer W, Resnick NM. Cerebral control of the bladder in normal and urge-incontinent women. Neuroimage. 2007; 37: 1-7.
- 32Yang Z, Dolber PC, Fraser MO. Differential vulnerabilities of urethral afferents in diabetes and discovery of a novel urethra-to-urethra reflex. Am J Physiol Renal Physiol. 2010; 298: F118-F124.
- 33Suskind AM. The aging overactive bladder: a review of aging-related changes from the brain to the bladder. Curr Bladder Dysfunct Rep. 2017; 12: 42-47.
- 34Siroky MB. The aging bladder. Rev Urol. 2004; 6(Suppl 1): S3-S7.
- 35Yoshida M, Homma Y, Inadome A, et al. Age-related changes in cholinergic and purinergic neurotransmission in human isolated bladder smooth muscles. Exp Gerontol. 2001; 36: 99-109.
- 36Mansfield KJ, Liu L, Mitchelson FJ, Moore KH, Millard RJ, Burcher E. Muscarinic receptor subtypes in human bladder detrusor and mucosa, studied by radioligand binding and quantitative competitive RT-PCR: changes in ageing. Br J Pharmacol. 2005; 144: 1089-1099.
- 37Tyagi P, Tyagi V, Qu X, et al. Association of inflammaging (inflammation + aging) with higher prevalence of OAB in elderly population. Int Urol Nephrol. 2014; 46: 871-877.
- 38Greenland JE, Brading AF. Urinary bladder blood flow changes during the micturition cycle in a conscious pig model. J Urol. 1996; 156: 1858-1861.
- 39Greenland JE, Brading AF. The effect of bladder outflow obstruction on detrusor blood flow changes during the voiding cycle in conscious pigs. J Urol. 2001; 165: 245-248.
- 40Ponholzer A, Temml C, Wehrberger C, Marszalek M, Madersbacher S. The association between vascular risk factors and lower urinary tract symptoms in both sexes. Eur Urol. 2006; 50: 581-586.
- 41Zhang Q, Siroky M, Yang JH, Zhao Z, Azadzoi K. Effects of ischemia and oxidative stress on bladder purinoceptors expression. Urology. 2014; 84: 1249.e1-1249.e7.
- 42Azadzoi KM, Shinde VM, Tarcan T, Kozlowski R, Siroky MB. Increased leukotriene and prostaglandin release, and overactivity in the chronically ischemic bladder. J Urol. 2003; 169: 1885-1891.
- 43Azadzoi KM, Yalla SV, Siroky MB. Oxidative stress and neurodegeneration in the ischemic overactive bladder. J Urol. 2007; 178: 710-715.
- 44Azadzoi KM, Chen BG, Radisavljevic ZM, Siroky MB. Molecular reactions and ultrastructural damage in the chronically ischemic bladder. J Urol. 2011; 186: 2115-2122.
- 45Hauser PJ, Dozmorov MG, Bane BL, Slobodov G, Culkin DJ, Hurst RE. Abnormal expression of differentiation related proteins and proteoglycan core proteins in the urothelium of patients with interstitial cystitis. J Urol. 2008; 179: 764-769.
- 46Apostolidis A, Jacques TS, Freeman A, et al. Histological changes in the urothelium and suburothelium of human overactive bladder following intradetrusor injections of botulinum neurotoxin type A for the treatment of neurogenic or idiopathic detrusor overactivity. Eur Urol. 2008; 53: 1245-1253.
- 47Lowe EM, Anand P, Terenghi G, Williams-Chestnut RE, Sinicropi DV, Osborne JL. Increased nerve growth factor levels in the urinary bladder of women with idiopathic sensory urgency and interstitial cystitis. Br J Urol. 1997; 79: 572-577.
- 48Liu HT, Jiang YH, Kuo HC. Increased serum adipokines implicate chronic inflammation in the pathogenesis of overactive bladder syndrome refractory to antimuscarinic therapy. PLoS One. 2013; 8: e76706.
- 49Tyagi P, Barclay D, Zamora R, et al. Urine cytokines suggest an inflammatory response in the overactive bladder: a pilot study. Int Urol Nephrol. 2010; 42: 629-635.
- 50Brown JS, Grady D, Ouslander JG, Herzog AR, Varner RE, Posner SF. Prevalence of urinary incontinence and associated risk factors in postmenopausal women. Heart & Estrogen/Progestin Replacement Study (HERS) Research Group. Obstet Gynecol. 1999; 94: 66-70.
- 51Brown JS, McGhan WF, Chokroverty S. Comorbidities associated with overactive bladder. Am J Manag Care. 2000; 6(Suppl): S574-S579.
- 52Reynolds WS, Mock S, Zhang X, et al. Somatic syndromes and chronic pain in women with overactive bladder. Neurourol Urodyn. 2017; 36: 1113-1118.
- 53Choi JB, Yoon BI, Han KD, Hong SH, Ha US. Urinary incontinence is associated with the development of peptic ulcers in adult women: data from the KNHANES IV. Medicine (Baltimore). 2017; 96: e8266.
- 54Baron R, Hans G, Dickenson AH. Peripheral input and its importance for central sensitization. Ann Neurol. 2013; 74: 630-636.
- 55Caterina MJ, Schumacher MA, Tominaga M, Rosen TA, Levine JD, Julius D. The capsaicin receptor: a heat-activated ion channel in the pain pathway. Nature. 1997; 389: 816-824.
- 56Avelino A, Cruz C, Nagy I, Cruz F. Vanilloid receptor 1 expression in the rat urinary tract. Neuroscience. 2002; 109: 787-798.
- 57Majima T, Funahashi Y, Takai S, et al. Herpes simplex virus vector-mediated gene delivery of poreless TRPV1 channels reduces bladder overactivity and nociception in rats. Hum Gene Ther. 2015; 26: 734-742.
- 58Birder LA, deGroat WC. Increased c-fos expression in spinal neurons after irritation of the lower urinary tract in the rat. J Neurosci. 1992; 12: 4878-4889.
- 59Munoz A, Somogyi GT, Boone TB, Smith CP. Central inhibitory effect of intravesically applied botulinum toxin A in chronic spinal cord injury. Neurourol Urodyn. 2011; 30: 1376-1381.
- 60Chalaye P, Goffaux P, Bourgault P, et al. Comparing pain modulation and autonomic responses in fibromyalgia and irritable bowel syndrome patients. Clin J Pain. 2012; 28: 519-526.
- 61Hubeaux K, Deffieux X, Raibaut P, Le Breton F, Jousse M, Amarenco G. Evidence for autonomic nervous system dysfunction in females with idiopathic overactive bladder syndrome. Neurourol Urodyn. 2011; 30: 1467-1472.
- 62Aydogmus Y, Uzun S, Gundogan FC, Ulas UH, Ebiloglu T, Goktas MT. Is overactive bladder a nervous or bladder disorder? Autonomic imaging in patients with overactive bladder via dynamic pupillometry. World J Urol. 2017; 35: 467-472.
- 63Raj SR. The postural tachycardia syndrome (POTS): pathophysiology, diagnosis & management. Indian Pacing Electrophysiol J. 2006; 6: 84-99.
- 64Kaufman MR, Chang-Kit L, Raj SR, et al. Overactive bladder and autonomic dysfunction: lower urinary tract symptoms in females with postural tachycardia syndrome. Neurourol Urodyn. 2017; 36: 610-613.